A Phase 2 interventional study of hydrocortisone and dextrose solution 5% in Cirrhosis With Ascites, sponsored by University of Turin, Italy. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-14.
Sponsored by University of Turin, Italy · Phase 2, Interventional, and Treatment
Relative adrenal insufficiency (RAI) is an well known condition in patients with septic shock. Liver failure (including chronic liver failure)and sepsis are both characterized by hyperdynamic circulatory failure (with low arterial pressure) and high levels of pro-inflammatory cytokines.
Hydrocortisone has been shown to have a beneficial effect on clinical outcome. The aim of this study is to evaluate the incidence of RAI in the different settings of ascites in cirrhosis and the usefulness of hydrocortisone in this context.
132 studies on the registry are indexed under Adrenal Insufficiency; 26 are open to participants now.
This study's planned enrollment of 50 is above the median of 37 across 70 interventional studies indexed under Adrenal Insufficiency.
Browse Adrenal Insufficiency studies →University of Turin, Italy is the lead sponsor of 206 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Hydrocortisone, 50 mg/6 h per day
Drug: hydrocortisone
dextrose solution 5%
Drug: dextrose solution 5%
50 mg/6 h per day
dextrose solution 5% 100 ml/6 h per day
renal function
Time frame: 10 days
This study is status unknown, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Turin, Italy